瘤组织NPR1基因表达变化与乳腺癌、卵巢癌预后关系的大数据分析
|
摘要
目的探讨乳腺癌、卵巢癌组织NPR1基因表达变化与乳腺癌、卵巢癌预后的关系。方法用Oncomine数据库分析乳腺癌组织、卵巢癌组织和正常组织中NPR1基因表达的差异,用Kaplan-Meier Plotter数据库进行乳腺癌、卵巢癌患者生存分析,分析乳腺癌、卵巢癌组织NPR1基因表达变化与乳腺癌、卵巢癌预后的关系。结果 Oncomine数据库包含了715个数据集和86 733个样本。大数据分析结果显示正常乳腺组织中NPR1基因高表达,乳腺癌组织中NPR1基因低表达。正常卵巢组织中NPR1基因低表达,卵巢癌组织中NPR1基因高表达。KaplanMeier Plotter数据库包含了54 675个基因和10 461个癌症样本信息,其中包含5 143个乳腺癌患者样本,1 861个卵巢癌患者样本。大数据分析结果显示乳腺癌组织NPR1基因高表达的患者无病生存时间较长(P<0.05)。基底样型乳腺癌、腺腔B型乳腺癌和HER2过表达型乳腺癌NPR1基因低表达和高表达患者预后无明显差异(P均>0.05);腺腔A型乳腺癌患者NPR1高表达预后明显好于低表达者(P<0.05)。卵巢癌组织NPR1基因低表达者的无进展生存时间比高表达者长(P<0.05)。具体细分,浆液性卵巢癌和子宫内膜性卵巢癌组织NPR1基因低表达者的预后明显好于高表达者(P均<0.05)。结论乳腺癌组织NPR1基因高表达提示预后良好,而卵巢癌组织NPR1基因高表达提示预后不良。
Objective To discuss the relationship between the expression of NPR1 gene and prognosis in tissues of breast cancer and ovarian cancer. Methods Using Oncomine database to analyze the differences of NPR1 gene in the breast cancer tissues,ovarian cancer tissues,and normal tissues. The prognostic roles of NPR1 in breast and ovarian cancer were analyzed by using Kaplan-Meier Plotter database,and then we analyzed the relationship between the expression of NPR1 gene and prognosis in tissues of breast cancer and ovarian cancer. Results Oncomine database included 715 data sets and 86 733 samples. Compared with the normal breast tissues,the expression of NPR1 gene decreased in different types of breast cancer; compared with the normal ovarian tissues,the expression of NPR1 gene in the ovarian cancer increased. Kaplan-Meier Plotter Database consisted of 54 675 genes and 10 461 cancer samples,including 5 143 samples taken from patients with breast cancer and 1 861 samples taken from patients with ovarian cancer. As the big data showed,disease-free survival time of breast cancer patients with high expression of NPR1 was longer( P < 0. 05); in different molecular subtypes of breast cancer,there were no significant differences between NPR1 low expression and high expression in the prognosis of patients with basal-like breast cancer,luminal B breast cancer,and HER2 over-expressing breast cancer( all P > 0. 05); the prognosis of luminal A breast cancer patients with high expression of NPR1 was better than that of patients with low expression of NPR1( P < 0. 05). However,in ovarian cancer patients,it was just the opposite: progressionfree survival time of patients with NPR1 low expression was longer. Specifically,the prognosis of patients with serous ovarian cancer and endometrial carcinoma with low expression of NPR1 was better than that of patients with high expression of NPR1( all P < 0. 05). Conclusion The high expression of NPR1 gene in the breast cancer tissues suggests that the prognosis is good,while the high expression of NPR1 gene in ovarian cancer shows poor prognosis.
Objective To discuss the relationship between the expression of NPR1 gene and prognosis in tissues of breast cancer and ovarian cancer. Methods Using Oncomine database to analyze the differences of NPR1 gene in the breast cancer tissues,ovarian cancer tissues,and normal tissues. The prognostic roles of NPR1 in breast and ovarian cancer were analyzed by using Kaplan-Meier Plotter database,and then we analyzed the relationship between the expression of NPR1 gene and prognosis in tissues of breast cancer and ovarian cancer. Results Oncomine database included 715 data sets and 86 733 samples. Compared with the normal breast tissues,the expression of NPR1 gene decreased in different types of breast cancer; compared with the normal ovarian tissues,the expression of NPR1 gene in the ovarian cancer increased. Kaplan-Meier Plotter Database consisted of 54 675 genes and 10 461 cancer samples,including 5 143 samples taken from patients with breast cancer and 1 861 samples taken from patients with ovarian cancer. As the big data showed,disease-free survival time of breast cancer patients with high expression of NPR1 was longer( P < 0. 05); in different molecular subtypes of breast cancer,there were no significant differences between NPR1 low expression and high expression in the prognosis of patients with basal-like breast cancer,luminal B breast cancer,and HER2 over-expressing breast cancer( all P > 0. 05); the prognosis of luminal A breast cancer patients with high expression of NPR1 was better than that of patients with low expression of NPR1( P < 0. 05). However,in ovarian cancer patients,it was just the opposite: progressionfree survival time of patients with NPR1 low expression was longer. Specifically,the prognosis of patients with serous ovarian cancer and endometrial carcinoma with low expression of NPR1 was better than that of patients with high expression of NPR1( all P < 0. 05). Conclusion The high expression of NPR1 gene in the breast cancer tissues suggests that the prognosis is good,while the high expression of NPR1 gene in ovarian cancer shows poor prognosis.
引文
[1]Jemal A,Bray F,Center MM,et al.Global cancer statistics.CA Cancer J Clin,2011,61(2):69-90.
[2]Smith RA,Andrews K,Brooks D,et al.Cancer screening in the United States,2016:A review of current American Cancer Society guidelines and current issues in cancer screening[J].CA Cancer J Clin,2016,66(2):96-11
[3]Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[4]郭新华,王敬章,赵朝贤,等.扩张型心肌病心力衰竭患者npr1基因G1023C多态性对重组人B型利钠肽疗效的影响[J].广东医学,2014,28(21):3318-3321.
[5]Scott NJ,Ellmers LJ,Lainchbury JG,et al.Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development[J].Biochim Biophys Acta,2009,1792(12):1175-84.
[6]张利芸,陈娟,陈曼华,等.ANP/NPRA基因多态性与心肌梗死后心力衰竭的相关性研究[J].重庆医学,2011,(12):1156-1158-1161.
[7]赵志龙,张佳,叶尔买克·唐沙哈尔,等.NPRA与肿瘤相关性的研究进展[J].医学综述,2013,23(2):285-287.
[8]Zhang J,Li M,Yang Y,et al.NPR-A:a therapeutic target in inflammation and cancer[J].Crit Rev Eukaryot Gene Expr,2015,25(1):41-6.
[9]Kong X,Wang X,Xu W,et al.Natriuretic peptide receptor a as a novel anticancer target[J].Cancer Res,2008,68(1):249-256.
[10]De Caprio JA,Ludlow JW,Lynch D,et al.The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element[J].Cell,1989,58(6):1085-1095.
[11]Rhodes DR,Yu J,Shanker K,et al.ONCOMINE:a cancer microarray database and integrated data-mining platform[J].Neoplasia,2004,6(1):1-6.
[12]Gyorffy B,Lanczky A,Szallasi Z.Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients[J].Endocr Relat Cancer,2012,19(2):197-208.
[13]Yang H,Zhang X,Cai XY,et al.From big data to diagnosis and prognosis:gene expression signatures in liver hepatocellular carcinoma[J].Peer J,2017,38(5):3089.
[2]Smith RA,Andrews K,Brooks D,et al.Cancer screening in the United States,2016:A review of current American Cancer Society guidelines and current issues in cancer screening[J].CA Cancer J Clin,2016,66(2):96-11
[3]Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[4]郭新华,王敬章,赵朝贤,等.扩张型心肌病心力衰竭患者npr1基因G1023C多态性对重组人B型利钠肽疗效的影响[J].广东医学,2014,28(21):3318-3321.
[5]Scott NJ,Ellmers LJ,Lainchbury JG,et al.Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development[J].Biochim Biophys Acta,2009,1792(12):1175-84.
[6]张利芸,陈娟,陈曼华,等.ANP/NPRA基因多态性与心肌梗死后心力衰竭的相关性研究[J].重庆医学,2011,(12):1156-1158-1161.
[7]赵志龙,张佳,叶尔买克·唐沙哈尔,等.NPRA与肿瘤相关性的研究进展[J].医学综述,2013,23(2):285-287.
[8]Zhang J,Li M,Yang Y,et al.NPR-A:a therapeutic target in inflammation and cancer[J].Crit Rev Eukaryot Gene Expr,2015,25(1):41-6.
[9]Kong X,Wang X,Xu W,et al.Natriuretic peptide receptor a as a novel anticancer target[J].Cancer Res,2008,68(1):249-256.
[10]De Caprio JA,Ludlow JW,Lynch D,et al.The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element[J].Cell,1989,58(6):1085-1095.
[11]Rhodes DR,Yu J,Shanker K,et al.ONCOMINE:a cancer microarray database and integrated data-mining platform[J].Neoplasia,2004,6(1):1-6.
[12]Gyorffy B,Lanczky A,Szallasi Z.Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients[J].Endocr Relat Cancer,2012,19(2):197-208.
[13]Yang H,Zhang X,Cai XY,et al.From big data to diagnosis and prognosis:gene expression signatures in liver hepatocellular carcinoma[J].Peer J,2017,38(5):3089.